Drug Type Small molecule drug |
Synonyms 2'-Deoxy-2'-(fluoromethylene)cytidine, FMdc, Tezacitabine (USAN) + [5] |
Target |
Mechanism POLA1 inhibitors(DNA polymerase alpha subunit inhibitors), RNR inhibitors(Ribonucleotide reductase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC10H14FN3O5 |
InChIKeyXPYQFIISZQCINN-QVXDJYSKSA-N |
CAS Registry171176-43-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06100 | Tezacitabine | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma | Phase 2 | US | 01 Nov 2003 | |
Advanced Gastric Adenocarcinoma | Phase 2 | US | 01 Nov 2003 | |
Esophageal Carcinoma | Phase 2 | US | 01 Nov 2003 | |
Metastatic Colorectal Carcinoma | Phase 2 | US | 01 Jun 2003 | |
Acute Myeloid Leukemia | Phase 2 | US | - | - |
Colonic Cancer | Phase 2 | - | - | |
Colonic Cancer | Phase 2 | - | - | |
Colonic Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | US | - | - |
Non-Small Cell Lung Cancer | Phase 2 | - | - |